The expression of survivin in patients with B-cell chronic lymphocytic leukemia (B-CLL)

Acta Haematologica Polonica

Volumn 36, Issue SUPPL. 1, 2005, Pages 83-88

  Giannopoulos, Krzysztof ^a,b   Dmoszyńska, Anna ^b   Roliński, Jacek ^b   Hus, Iwona ^b   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

B cell chronic lymphocytic leukemia (B CLL); Baculovirus IAP repeat (BIR); Inhibitors of apoptosis proteins (IAP); Leukemia associated antigens (LAAs); Survivin; Tumor associated antigens(TAAs)

Indexed keywords

CD19 ANTIGEN; CD40 LIGAND; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; SURVIVIN; TUMOR ANTIGEN;

B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOTHERAPY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 27144457754     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Dighiero G, Binet JL. Chronic lymphocytic leukemia. Hematol Cell Ther 1996; 38: S41-61.
2. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003; ASH Educational Program: 153-75.
3. Ambrosini G, Adida C, and Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
4. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 2002; 4: 317-27.
5. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-6.
6. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170 : 5391-7.
7. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004; 28: 487-94.
8. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-83.
9. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 2004; 104: 4002-9.
10. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Dmoszyńska A, Wa̧sik-Szczepanek E. Immunotherapy of Patients with B-CLL in early stage with allogeneic dendritic cells pulsed with tumor lysates - preliminary report. Leuk Lymph 2003; 44: S31 (Abstr.).
11. Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner CM. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005; 105: 1566-73.
12. Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J Jr, Barsoum A, Rohrer J, Schmitz N, Zeis M. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003; 102: 4416-23.
13. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
14. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
15. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999; 93: 1992-2002.
16. Krackhardt AM, Hang S, Witzens M, Broderick R, Barrett P, Gribben JG. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002; 100: 167-73.
17. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer 2004; 108: 937-41.
18. Caligaris-Cappio F. B-chronic lymphatic leukemia: A malignancy of anti-self B cells. Blood 1996; 87: 2615-20.